Search Tips

Genetic analysis of HLA and immune escape genes in Diffuse Large B-cell Lymphoma

UID: 10739

Study Description from EGA: "Fifty percent of diffuse large B-cell lymphoma (DLBCL) cases lack cell-surface expression of the class-I major histocompatibility complex (MHC-I), thereby escaping immune recognition by cytotoxic T cells. In order to comprehensively identify the mechanisms involved in MHC-I loss, we first performed immunophenotypic analysis of both MHC class-I and -II in 657 cases across the spectrum of B-NHL, revealing that loss of MHC-I, but not MHC-II, is preferentially restricted to DLBCL. We then used whole exome and targeted deep-sequencing to examine genes involved in MHC-I expression in 74 DLBCL samples representative of MHC-I positive and negative cases. We show here that somatic biallelic or monoallelic inactivation of B2M and/or HLA-I is present in 80.9% (34/42) of MHC-I negative tumors. Furthermore, 68.8% (22/32) of MHC-I positive DLBCLs also harbored monoallelic HLA-I genetic alterations (MHC-I positivemono) that lead to allelic imbalance, suggesting allele-specific inactivation. Both MHC-I negative and MHC-I positivemono cases showed a significantly higher mutational burden as well as a higher number of inferred neo-antigens, suggesting co-selection of HLA-I loss and sustained neo-antigen production. Interestingly, the analysis of > 500.000 individuals in two databases revealed homozygosity of germline HLA-I genes in 26-38% of DLBCL patients, a frequency significantly higher than that observed in any other cancer type. In mice, germinal-center B cells lacking HLA-I expression did not progress to lymphoma and were counterselected in the context of oncogene-driven lymphomagenesis, suggesting that additional events are needed to license immune evasion. These results suggest a multi-step process of HLA-I loss including both germ-line and somatic events in DLBCL development, and have direct implications for the pathogenesis and immunotherapeutic targeting of this disease. "

Dataset description: "
We performed genetic analysis of HLA and immune escape genes in samples from 44 patients sequenced by whole exome sequencing (34 tumor samples, 32 normal samples) and whole genome sequencing (10 tumor samples, 12 normal samples). We also performed HLA targeted sequencing in 26/44 patients (26 tumor samples, 26 normal samples). "
Subject of Study
OncoTree Cancer Type(s)
Diffuse Large B-Cell Lymphoma, NOS
Access via EGA

WXS and WGS Sequencing data
Accession #: EGAS00001005054

Access Restrictions
Application Required
Access Instructions
The European Genome-Phenome Archive (EGA) provides a service for the permanent archiving and distribution of personally identifiable genetic and phenotypic data resulting from biomedical research projects. Data at EGA was collected from individuals whose consent agreements authorise data release only for specific research use to bona fide researchers. Strict protocols govern how information is managed, stored and distributed by the EGA project.

To view dataset file format, size, location and QC Report click on the 'Browse files' button aligned to the right of the dataset title. A Comma Separated Value (CSV) file of this information can be downloaded.

Each dataset is covered by a Data Access Agreement (DAA), which defines the terms and conditions of use for the specified dataset. Specific requirements for access to the dataset are represented by buttons representing terms covered by the 'Data Use Conditions' in the link below.

To access files an EGA account is created by the DAC for an individual user, in response to a successful application to access single or multiple datasets. Datasets are downloaded using the EGA Download Client, which provides instant access to all approved files, which may be filtered and downloaded by dataset.

Studies associated with the dataset are listed and linked by accession numbers at the bottom of the page.
Associated Publications
Data Type
Equipment Used
Illumina HiSeq 2000
Data Tool(s)
Data Catalog Record Updated